NCT00383786View on ClinicalTrials.gov

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
PTSD
Interventions
DRUG

NK1 Antagoist (GR205171)

PROCEDURE

Psychophysiology (Trauma Script)

PROCEDURE

Psychophysiology (Verbal Threat)

PROCEDURE

Psychophysiology (Fear Conditioning)

PROCEDURE

Psychophysiology (Affective Modulation)

PROCEDURE

Psychophysiology (Heart rate variability)

PROCEDURE

Lumbar Puncture

PROCEDURE

24-hour plasma sampling

PROCEDURE

MRI

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

10029-0574

Mt. Sinai Medical Center, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Baylor College of Medicine

OTHER

NCT00383786 - Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder | Biotech Hunter | Biotech Hunter